Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11207 for the treatment of Parkinson's disease. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.
Frequently asked questions
What sector does Aeolus Pharmaceuticl (AOLS) operate in?
Aeolus Pharmaceuticl belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Aeolus Pharmaceuticl (AOLS) current stock price?
As of the latest data, Aeolus Pharmaceuticl stock price is $0.00, with a previous close of $0.00.
What is Aeolus Pharmaceuticl (AOLS) current market capitalization?
Aeolus Pharmaceuticl market cap is approximately 15.21 thousand.
Does Aeolus Pharmaceuticl (AOLS) pay dividends?
No. Aeolus Pharmaceuticl does not pay a dividend.
What is Aeolus Pharmaceuticl (AOLS) beta (volatility) score?
Aeolus Pharmaceuticl has a beta of -64.364, indicating lower volatility than the overall market.
